What Plasma Services Group does

Plasma Services Group, Inc. (PSG) is a Moorestown, New Jersey-based specialty biological materials supplier and clinical laboratory serving the in vitro diagnostics (IVD) and life sciences industries. The company's core function is the collection, screening, processing, storage, and distribution of disease-state plasma — human plasma from donors with specifically characterized antibody profiles — used by IVD manufacturers for assay development, quality control, and kit manufacturing. PSG maintains an inventory of more than 1,500 serologically defined plasma units covering 60+ antibody specificities and screens 75-100 donors monthly for up to 25 diseases through a two-fold prospective and active donor recruitment model. Complementary offerings include custom plasma processing (defibrination, delipidization, pooling), biobanking of pre-qualified units, validation and clinical sample panels, and full-service clinical laboratory testing in immunology, hematology, microbiology, and molecular diagnostics performed by ASCP-certified Medical Technologists.

PSG operates a hybrid revenue model across five streams: (1) B2B disease-state plasma and processed/custom plasma sales to IVD manufacturers and research organizations on a quote-based, per-unit basis; (2) clinical laboratory testing services billed as professional services to support clinical trials, validation, beta testing, and safety advisory work; (3) exclusive distribution of IUIS Autoantibody Standardization Committee reference standards (in cooperation with the CDC) for autoantibody specificity testing; (4) direct-to-consumer health screening packages (Basic Care $90, Essential Care $190, Total Care $290); and (5) donor-side compensation economics (donors receive $200 per future donation) that underwrites the supply side of the plasma funnel. Distribution runs primarily through a small direct sales team (Nichelle Porto, Kate Boylan, Tony Zamparelli, Kathryn Kohl) contacting enterprise IVD buyers by phone and email, supplemented by conference presence (AACC, AMLI, MEDICA, International Congress on Autoimmunity) and a B2C donor/consumer website (PSGDonors.com).

Regulatory and quality positioning is central to PSG's value proposition: the company holds FDA Blood Establishment Registration (number 300527238), ISO 9001:2015 certification, and compliance with US FDA 21 CFR §820 Quality System Regulations — credentials that, per company materials, only a handful of US donor centers can match for legally bleeding donors with clinically identified disease states. The company was founded in 2004 by Jeffrey Fleishman, transitioned to majority ownership by Katherine Boylan and Nichelle Fernandez in 2018-2021, and was acquired by Fujirebio Holdings, Inc. (a Japanese diagnostics company) in June 2025, under which PSG now operates as a wholly-owned subsidiary.

Name

Plasma Services Group

Legal name

Plasma Services Group, Inc.

Website

https://plasmaservicesgroup.com

Company type

Private

Founded year

2004

Operating status

Acquired

Headcount range

1–10 employees

Short description

Plasma Services Group is a Moorestown, NJ-based specialty biological materials supplier that collects, screens, processes, and distributes disease-state and reference plasma to in vitro diagnostic manufacturers, clinical research organizations, and individual consumers for assay development, validation, and health screening.

Ownership category

akta.pro rank

Headquarters

HQ city

Moorestown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Disease State Plasma Sales: Sale of specialty plasma collected from donors with specific disease conditions. PSG stocks over 1500 units of serologically defined plasma with over 60 different specificities. Materials include serologically defined bleeds, disease state plasma, and custom products collected/processed to customer specifications.
2. Laboratory Testing Services: Clinical laboratory services including immunology, hematology, microbiology, and molecular diagnostics testing. Services support clinical trials, validation and beta testing, and safety advisory services.
3. Plasma Processing Services: Custom processing of materials to customer specifications including defibrination, delipidization, and pooling. Also includes storage and inventorying of pre-qualified units.
4. Reference Standards Distribution: Distribution of IUIS-ANA reference standards for autoantibody specificities through PSG, in cooperation with CDC. Availability limited to 1 vial of each ANA reference per laboratory.
5. Health Check Packages: Direct-to-consumer health screening packages including Basic Care ($90), Essential Care ($190), and Total Care ($290).

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Plasma Services Group collects, processes, stores, and distributes human plasma with specific antibody profiles (disease state plasma) for use by in vitro diagnostic (IVD) manufacturers and research institutions in diagnostic kit development, quality control, and manufacturing. The company also provides custom plasma processing services (defibrination, delipidization, pooling), full-service clinical laboratory testing across immunology, hematology, microbiology, and molecular diagnostics, exclusive distribution of IUIS-ANA reference standards in cooperation with CDC, and direct-to-consumer health screening packages.

Product overview

Plasma Services Group operates as a medical and research diagnostics company offering a portfolio of biological materials and laboratory services for the IVD industry. The core product is Disease State Plasma — serologically defined plasma from donors with specific conditions — supplemented by Validation and Clinical Sample Panels and IUIS-ANA Reference Standards for autoantibody testing. These biological materials are complemented by Plasma Processing Services (defibrination, delipidization, pooling) and BioBanking Services for storage and inventory management. The company also provides Clinical Laboratory Testing Services across immunology, hematology, microbiology, and molecular diagnostics, plus Health Check Packages for diagnostic screening. In June 2025, Plasma Services Group was acquired by Fujirebio Holdings, Inc. to strengthen its biological raw materials supply for the IVD and life science industries.

Differentiator

Problem solved

Functional benefit

Products and services

• Disease State Plasma Serologically defined plasma collected from donors with specific diseases, used in R&D, quality control, and manufacturing within the IVD industry. PSG maintains an inventory of over 1,500 units spanning 60+ antibody specificities.
• Validation and Clinical Sample Panels Pre-qualified plasma units used for assay validation and clinical testing purposes by IVD manufacturers.
• IUIS-ANA Reference Standards Reference standards for autoantibody specificities, distributed exclusively through PSG in cooperation with the IUIS Autoantibody Standardization Committee and the CDC. Includes anti-mitochondrial and anti-rods/rings autoantibodies. Availability limited to 1 vial per laboratory.
• Plasma Processing Services Custom processing including defibrination, delipidization, and pooling materials to customer specifications, with storage and inventorying of pre-qualified units.
• Clinical Laboratory Testing Services Full-service laboratory offering immunology, hematology, microbiology, and molecular diagnostics testing for clinical trials, validation and beta testing, and safety advisory services. Performed by ASCP-certified Medical Technologists.
• Health Check Packages Tiered health screening packages for individual consumers including Basic Care ($90) for complete blood count, liver function, heart disease, cholesterol/lipid, STD, and metabolic panels; Essential Care ($190) Gold Health Check with CBC; and Total Care ($290) Platinum Health Check with CBC.
• Research Testing for Clinical Trials Laboratory testing services supporting clinical trials with assay validation and beta testing capabilities for research institutions and CROs.
• BioBanking Services Storage and inventory management of pre-qualified plasma units for future purchase at no additional cost.
• Donor Screening Services Screening of donors in customer-specific test kits to identify and qualify specialty plasma donors. PSG screens 75-100 donors per month for up to 25 different diseases.

Quantifiable outcome

• Over 1,500 units of serologically defined plasma available with 60+ specificities
• +1 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Fujirebio Holdings, Inc.coreStrategic or Co-development Partner · 20 June 2025Fujirebio Holdings, Inc. acquired Plasma Services Group in June 2025. The acquisition aims to create synergies by combining biological materials and samples, strengthening Fujirebio's position as a provider of biological raw materials to the IVD and life science industries. Plasma Services Group now operates as a subsidiary of Fujirebio.
• American Red CrosscoreStrategic or Co-development PartnerStrategic business relationship established to distribute American Red Cross viral and syphilis marker deferred plasma units. This partnership enhances PSG's product offerings by providing access to additional plasma sources.
• IUIS Autoantibody Standardization Committee (ASC)coreStrategic or Co-development PartnerPSG serves as the exclusive distributor for IUIS Autoantibody Standardization Committee reference standards for autoantibody specificities. The ASC, in cooperation with the Centers for Disease Control (CDC) USA, makes reference standards available through PSG. In addition to the 17 reference reagents previously available from CDC, PSG generates and distributes new reference reagents including anti-mitochondrial and anti-rods/rings autoantibodies.
• Centers for Disease Control and Prevention (CDC)coreStrategic or Co-development PartnerCDC cooperates with the IUIS Autoantibody Standardization Committee to make reference standards available through PSG. PSG distributes reference reagents previously available from CDC, with new reagents being generated and distributed by PSG.
• Novalab (NovaLab)minorOthersNovaLab provides laboratory testing services referenced on PSG's services page. The relationship appears to be a service provider partnership for clinical laboratory testing including immunology, hematology, and microbiology services.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Grifols: Global plasma collection and plasma-derived therapeutics leader operating hundreds of donor centers. Comparable as a large-scale plasma collector, though Grifols focuses on therapeutic fractionation rather than IVD-specific disease-state plasma.
• CSL Behring: Major plasma collection and fractionation company through its parent CSL Limited. Overlaps with PSG in plasma sourcing infrastructure but targets therapeutic end markets at much larger scale.
• Octapharma: Privately held plasma fractionator with donor centers across the US and Europe. Comparable as a plasma collector for human plasma-derived products, though focused on therapeutic proteins rather than IVD raw materials.
• Bio-Rad Laboratories: Major IVD manufacturer and supplier of quality controls, reference materials, and immunoassay reagents. Comparable as a buyer and competitor in the IVD materials ecosystem, particularly for autoimmune diagnostics.

Direct peers

• SeraCare (LGC Clinical Diagnostics): Provider of biological materials, reference standards, and controls for the IVD and life-science industries. Closely matches PSG's specialty biological-materials and reference-standard distribution model for diagnostic manufacturers.
• HemaCare (Charles River Laboratories): Supplier of human-derived biological products including disease-state plasma and apheresis collections for research and IVD use. Now part of Charles River, offering comparable specialty plasma and cellular materials.
• Immucor: Specialty diagnostics company focused on transfusion and transplant immunology, sourcing rare antibody-positive blood products. Overlaps with PSG in donor-sourced specialty biologicals for the diagnostics industry.

Regional players

• Diagnostica Stago: Privately held French specialty diagnostics company focused on hemostasis and coagulation testing. Comparable as a specialty IVD player with related autoimmune/coagulation reagent portfolios, though more regionally focused on Europe.

Emerging players

• Trina Bioreactives: Specialty supplier of human plasma and serum products for IVD manufacturers, including disease-state and normal donor materials. Comparable as a niche peer in disease-state plasma sourcing for diagnostic kit developers.
• ZenBio: Supplier of human biological samples including plasma and serum for research and diagnostics applications. Comparable as a small specialty biological-materials supplier to IVD and life-science customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PlasmaServices

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Plasma Services Group